CYP 2021 - The year ahead, page-106

Agreed, confirmation of the efficacy of MSC's is slowly building. There is:

Crohns disease (Alofisel which is approved in Europe/UK)

GVHD (approved in Japan and in the USA the ODAC voted 9:1 that it works for pediatric patients with steroid-refractory acute GVHD)

Chronic heart failure (MSB clinical trial found revascor provides a substantial and durable reduction in heart attacks, strokes and cardiac death)

As the list grows we should see more investors and money move into MSC/stem cell companies.

Cynata 6 month price target: $1.50 or just over a 200 million market cap based on new clinical trials starting and new partnerships.